Crossmark

Venetoclax-based low-intensity chemotherapy in the salvage treatment of relapsed/refractory T-cell acute lymphoblastic leukemia

Published Online: 2025-04-02

Authors

Xu, Fangfei

Bao, Xingshuo

Huang, Wei

Zhou, Kuangguo https://orcid.org/0000-0002-8309-5599
License Information

Text and Data Mining valid from 2025-04-02

Version of Record valid from 2025-04-02
More Information

Article History

Received: 24 January 2025

Accepted: 16 March 2025

First Online: 2 April 2025

Declarations

:

: The authors declare no competing interests.

: The studies involving human participants were reviewed and approved by the Ethical Review Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Ethics approval number: TJ-IRB20230886.

Document is current